// App-Quantinova.ai

: Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Researchers

Presenter

  • Peter Borchmann

Principal Investigators

  • Richard Greil

  • Mark Hertzberg

  • Valdete Schaub

  • Andreas Huttmann

  • Felix Keil

  • Judith Dierlamm

  • Mathias Haenel

  • Urban Novak

  • Julia Meissner

  • Andreas Zimmermann

  • Stephan Mathas

  • Josée M. Zijlstra

  • Alexander Fossa

  • Andreas Viardot

  • Bernd Hertenstein

  • Sonja Martin

  • Pratyush Giri

  • Peter Kamper

  • Daniel Molin

  • Stefanie Kreissl

  • Michael Fuchs

  • Gundolf Schneider

  • Andreas Rosenwald

  • Wolfram Klapper

  • Hans Eich

  • Christian Baues

  • Michael Hallek

  • Markus Dietlein

  • Carsten Kobe

  • Volker Diehl

  • Andreas Engert

Medical Centers

  • German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany

  • Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

  • rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark

  • Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany

  • University of Cologne, German Hodgkin Study Group (GHSG), Cologne, Germany

  • Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Salzburg, Austria and Cancer Cluster Salzburg (CCS), Salzburg, Austria

  • Department of Hematology/Oncology, University Hospital of Munich, LMU Munich, Munich, Germany

  • Department of Immunology, Genetics, and Pathology, Clinical and Experimental Oncology, Uppsala University, Uppsala Akademiska Hospital, Uppsala, Sweden

  • Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany

  • Department of Hematology and Oncology, Robert-Bosch-Hospital, Stuttgart, Germany

  • Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands, Amsterdam, Netherlands

  • Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

  • Department of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Kiel, Germany

  • Department of Hematology, Oncology and Bone Marrow Transplantation, Klinikum Chemnitz, Chemnitz, Germany

  • Medicine V, University of Heidelberg, Heidelberg, Germany

  • Royal Adelaide Hospital, Adelaide, Australia

  • AGMT, Salzburg, Austria

  • Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany

  • Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Department of Clinical Haematology, Westmead Hospital, Randwick, Australia

  • Division of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

  • Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany

  • Department of Nuclear Medicine. Faculty of Medicine and University of Cologne, Cologne, Germany

  • Faculty of Medicine and University Hospital Cologne, University Hospital of Cologne, Department of Nuclear Medicine, Cologne, Germany

  • University of Cologne, German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany

  • Department of Radiooncology and Cyberknife Center, Faculty of Medicine and University of Cologne, Cologne, Germany

  • Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Klinikum Bremen Mitte, Bremen, Germany

  • German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany

  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany

  • Medizinische Klinik II, Universitätsklinikum Tübingen, Tübingen, Germany

Locations

  • Germany

  • Austria

  • Switzerland

  • Netherlands

  • Denmark

  • Norway

  • Australia

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • Lymphomas

  • Anemia

Biomarkers

  • SSX Family Member 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • dacarbazine Intravenous

  • Doxorubicin

  • Etoposide

  • Etoposide phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Double Blind/Blinded

  • Open Label

  • Non Inferiority

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved